Evista
Evista is the brand name for raloxifene, a medication classified as a selective estrogen receptor modulator (SERM). It is primarily prescribed to postmenopausal women for the prevention and treatment of osteoporosis. By modulating the effects of estrogen in the body, Evista helps increase bone mineral density and reduce the risk of fractures, especially in the spine. Its dual action—mimicking estrogen in some tissues while blocking its effects in others—differentiates it from traditional hormone replacement therapy.
The main mechanism behind Evista involves binding to estrogen receptors in the bone, where it acts as an estrogen agonist. This helps decrease bone resorption and slow bone loss that often occurs after menopause. Unlike estrogen itself, however, raloxifene does not exhibit significant estrogenic activity in breast or uterine tissues. In fact, in breast tissue, it acts more like an estrogen antagonist, which can help reduce the risk of certain estrogen-dependent cancers.
Clinically, Evista is often considered an option for women who are specifically concerned about both bone health and breast cancer risk. It has been shown to lower the incidence of invasive breast cancer in postmenopausal women who have osteoporosis or are at high risk for the disease. While this dual benefit makes Evista a valuable therapy, it is not approved for use in reducing the risk of all types of breast cancer, and it is not a suitable treatment for existing breast cancer.
The usual recommended dosing of Evista is a single oral tablet taken once daily. Patients are advised to maintain adequate calcium and vitamin D intake, either through diet or supplements, as part of an overall strategy to support bone health. Regular weight-bearing exercise, avoidance of smoking, and moderation of alcohol intake are also important lifestyle factors that can enhance the medication's effectiveness in improving or preserving bone density.
Evista is generally well-tolerated, but it does carry some potential side effects. Hot flashes and leg cramps are among the more frequently reported issues. A notable concern is the increased risk of venous thromboembolism (blood clots), which is a serious but relatively rare complication. Consequently, women with a history of deep vein thrombosis or pulmonary embolism are typically cautioned against using Evista. Additionally, because Evista is indicated for postmenopausal women, it is not recommended for use during pregnancy or while breastfeeding.
Overall, Evista represents an important therapeutic option for postmenopausal women seeking to protect their bone health and possibly reduce certain breast cancer risks. Its selective action on estrogen receptors allows it to deliver benefits similar to those of estrogen in bone without the full range of hormonal effects in other tissues. However, as with any medication, careful consideration of medical history and risk factors—along with regular follow-up—ensures that the therapy is both safe and effective for each individual patient.
NOTE: The above information is for marketing purposes only and is not to be construed as medical advice. Seek advice for medications from a qualified physician.
The main mechanism behind Evista involves binding to estrogen receptors in the bone, where it acts as an estrogen agonist. This helps decrease bone resorption and slow bone loss that often occurs after menopause. Unlike estrogen itself, however, raloxifene does not exhibit significant estrogenic activity in breast or uterine tissues. In fact, in breast tissue, it acts more like an estrogen antagonist, which can help reduce the risk of certain estrogen-dependent cancers.
Clinically, Evista is often considered an option for women who are specifically concerned about both bone health and breast cancer risk. It has been shown to lower the incidence of invasive breast cancer in postmenopausal women who have osteoporosis or are at high risk for the disease. While this dual benefit makes Evista a valuable therapy, it is not approved for use in reducing the risk of all types of breast cancer, and it is not a suitable treatment for existing breast cancer.
The usual recommended dosing of Evista is a single oral tablet taken once daily. Patients are advised to maintain adequate calcium and vitamin D intake, either through diet or supplements, as part of an overall strategy to support bone health. Regular weight-bearing exercise, avoidance of smoking, and moderation of alcohol intake are also important lifestyle factors that can enhance the medication's effectiveness in improving or preserving bone density.
Evista is generally well-tolerated, but it does carry some potential side effects. Hot flashes and leg cramps are among the more frequently reported issues. A notable concern is the increased risk of venous thromboembolism (blood clots), which is a serious but relatively rare complication. Consequently, women with a history of deep vein thrombosis or pulmonary embolism are typically cautioned against using Evista. Additionally, because Evista is indicated for postmenopausal women, it is not recommended for use during pregnancy or while breastfeeding.
Overall, Evista represents an important therapeutic option for postmenopausal women seeking to protect their bone health and possibly reduce certain breast cancer risks. Its selective action on estrogen receptors allows it to deliver benefits similar to those of estrogen in bone without the full range of hormonal effects in other tissues. However, as with any medication, careful consideration of medical history and risk factors—along with regular follow-up—ensures that the therapy is both safe and effective for each individual patient.
NOTE: The above information is for marketing purposes only and is not to be construed as medical advice. Seek advice for medications from a qualified physician.
EVISTA
Raloxifene
Generic: RALOXIFENE
Raloxifene
Generic: RALOXIFENE
60mg
28 TAB
28 TAB
$26.64